Attachment factors

Advances in Experimental Medicine and Biology

Volumn 790, Issue , 2013, Pages 1-23

  Jolly, Clare L ^a   Sattentau, Quentin J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATTACHMENT FACTOR; CD209 ANTIGEN; CD4 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LECTIN; LECTIN RECEPTOR; MEMBRANE PROTEIN; MEMBRANE RECEPTOR; PROTEOGLYCAN; RECEPTOR; SCAVENGER RECEPTOR; SIALIC ACID; TETRASPANIN; UNCLASSIFIED DRUG; VIRAL ATTACHMENT RECEPTOR; VIRUS PROTEIN;

ARTICLE; CELL INTERACTION; CYTOPLASM; FOOT AND MOUTH DISEASE VIRUS; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIGENS, CD4; CELL ADHESION MOLECULES; HUMANS; INTEGRINS; LECTINS, C-TYPE; N-ACETYLNEURAMINIC ACID; RECEPTORS, CELL SURFACE; RECEPTORS, VIRUS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 84881416344     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-7651-1_1     Document Type: Article

References (149)

1. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278(42):41003-41012.
2. Jones KS, Petrow-Sadowski C, Bertolette DC et al. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol 2005; 79(20):12692-12702.
3. Vlasak M, Goesler I, Blaas D. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. J Virol 2005; 79(10):5963-5970.
4. Saphire AC, Bobardt MD, Zhang Z et al. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 2001; 75(19):9187-9200.
5. Bobardt MD, Saphire AC, Hung HC et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003; 18(1):27-39.
6. Mondor I, Ugolini S, Sattentau QJ. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998; 72(5):3623-3634.
7. Spear PG, Shieh MT, Herold BC et al. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv Exp Med Biol 1992; 313:341-353.
8. WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 1989; 63(1):52-58.
9. Herold BC, WuDunn D, Soltys N et al. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol 1991; 65(3):1090-1098.
10. Lycke E, Johansson M, Svennerholm B et al. Binding of herpes simplex virus to cellular heparan sulphate, an initial step in the adsorption process. J Gen Virol 1991; 72(Pt 5):1131-1137.
11. Trybala E, Liljeqvist JA, Svennerholm B et al. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J Virol 2000; 74(19):9106-9114.
12. Gerber SI, Belval BJ, Herold BC. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. Virology 1995; 214(1):29-39.
13. Spear PG. Herpes simplex virus: Receptors and ligands for cell entry. Cell Microbiol 2004; 6(5):401-410.
14. Mardberg K, Trybala E, Glorioso JC et al. Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. J Gen Virol 2001; 82(Pt 8):1941-1950.
15. Laquerre S, Argnani R, Anderson DB et al. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998; 72(7):6119-6130.
16. Banfield BW, Leduc Y, Esford L et al. Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology 1995; 208(2):531-539.
17. Bergefall K, Trybala E, Johansson M et al. Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells. J Biol Chem 2005; 280(37):32193-32199.
18. Mardberg K, Trybala E, Tufaro F et al. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J Gen Virol 2002; 83(Pt 2):291-300.
19. Moulard M, Lortat-Jacob H, Mondor I et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74(4):1948-1960.
20. Vives RR, Imberty A, Sattentau QJ et al. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 2005; 280(22):21353-21357.
21. Zhang YJ, Hatziioannou T, Zang T et al. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002; 76(12):6332-6343.
22. Ugolini S, Mondor I, Sattentau QJ. HIV-1 attachment: Another look. Trends Microbiol 1999; 7(4):144-149.
23. Fouts TR, Trkola A, Fung MS et al. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: Relationship to neutralization. AIDS Res Hum Retroviruses 1998; 14(7):591-597.
24. Trkola A, Gordon C, Matthews J et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol 1999; 73(8):6370-6379.
25. Pinon JD, Klasse PJ, Jassal SR et al. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 2003; 77(18):9922-9930.
26. Ohshiro Y, Murakami T, Matsuda K et al. Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type-1 (HIV-1) infection. Microbiol Immunol 1996; 40(11):827-835.
27. Igakura T, Stinchcombe JC, Goon PK et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299(5613):1713-1716.
28. Fry EE, Lea SM, Jackson T et al. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 1999; 18(3):543-554.
29. Sa-Carvalho D, Rieder E, Baxt B et al. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 1997; 71(7):5115-5123.
30. Fry EE, Newman JW, Curry S et al. Structure of Foot-and-mouth disease virus serotype A10 61 alone and complexed with oligosaccharide receptor: Receptor conservation in the face of antigenic variation. J Gen Virol 2005; 86(Pt 7):1909-1920.
31. Dechecchi MC, Melotti P, Bonizzato A et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75(18):8772-8780.
32. Dechecchi MC, Tamanini A, Bonizzato A et al. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 2000; 268(2):382-390.
33. Hildreth JE, Orentas RJ. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 1989; 244(4908):1075-1078.
34. Pantaleo G, Butini L, Graziosi C et al. Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. J Exp Med 1991; 173(2):511-514.
35. Fortin JF, Cantin R, Lamontagne G et al. Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997; 71(5):3588-3596.
36. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997; 71(6):4847-4851.
37. Zhu P, Chertova E, Bess Jr J et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci USA 2003; 100(26):15812-15817.
38. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998; 19(8):346-351.
39. Cantin R, Fortin JF, Lamontagne G et al. The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells. Blood 1997; 90(3):1091-1100.
40. Giguere JF, Bounou S, Paquette JS et al. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. J Virol 2004; 78(12):6222-6232.
41. Cantin R, Methot S, Tremblay MJ. Plunder and stowaways: Incorporation of cellular proteins by enveloped viruses. J Virol 2005; 79(11):6577-6587.
42. Kwong PD, Wyatt R, Robinson J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686):648-659.
43. Olshevsky U, Helseth E, Furman C et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990; 64(12):5701-5707.
44. Fouts TR, Binley JM, Trkola A et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997; 71(4):2779-2785.
45. Jeffs SA, Goriup S, Kebble B et al. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004; 22(8):1032-1046.
46. Kwong PD, Wyatt R, Sattentau QJ et al. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000; 74(4):1961-1972.
47. Berger EA. HIV entry and tropism: The chemokine receptor connection. Aids 1997; 11(Suppl A):S3-16.
48. Kolchinsky P, Mirzabekov T, Farzan M et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999; 73(10):8120-8126.
49. Staunton DE, Merluzzi VJ, Rothlein R et al. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989; 56(5):849-853.
50. Greve JM, Davis G, Meyer AM et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56(5):839-847.
51. Kolatkar PR, Bella J, Olson NH et al. Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 1999; 18(22):6249-6259.
52. Bella J, Kolatkar PR, Marlor CW et al. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc Natl Acad Sci USA 1998; 95(8):4140-4145.
53. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275(5304):1320-1323.
54. Svensson U, Persson R, Everitt E. Virus-receptor interaction in the adenovirus system I. Identification of virion attachment proteins of the HeLa cell plasma membrane. J Virol 1981; 38(1):70-81.
55. Tomko RP, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94(7):3352-3356.
56. Bewley MC, Springer K, Zhang YB et al. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999; 286(5444):1579-1583.
57. Bergelson JM, Shepley MP, Chan BM et al. Identification of the integrin VLA-2 as a receptor for echovirus. Science 1992; 255(5052):1718-1720.
58. Zimmermann H, Eggers HJ, Nelsen-Salz B. Cell attachment and mouse virulence of echovirus 9 correlate with an RGD motif in the capsid protein VP1. Virology 1997; 233(1):149-156.
59. Xing L, Huhtala M, Pietiainen V et al. Structural and functional analysis of integrin alpha2I domain interaction with echovirus 1. J Biol Chem 2004; 279(12):11632-11638.
60. King SL, Kamata T, Cunningham JA et al. Echovirus 1 interaction with the human very late antigen-2 (integrin alpha2beta1) I domain. Identification of two independent virus contact sites distinct from the metal ion-dependent adhesion site. J Biol Chem 1997; 272(45):28518-28522.
61. Coulson BS, Londrigan SL, Lee DJ. Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells. Proc Natl Acad Sci USA 1997; 94(10):5389-5394.
62. Jolly CL, Beisner BM, Holmes IH. Rotavirus infection of MA104 cells is inhibited by Ricinus lectin and separately expressed single binding domains. Virology 2000; 275(1):89-97.
63. Mendez E, Lopez S, Cuadras MA et al. Entry of rotaviruses is a multistep process. Virology 1999; 263(2):450-459.
64. Graham KL, Fleming FE, Halasz P et al. Rotaviruses interact with alpha4beta7 and alpha4beta1 integrins by binding the same integrin domains as natural ligands. J Gen Virol 2005; 86(Pt 12):3397-3408.
65. Hewish MJ, Takada Y, Coulson BS. Integrins alpha2beta1 and alpha4beta1 can mediate SA11 rotavirus attachment and entry into cells. J Virol 2000; 74(1):228-236.
66. Londrigan SL, Graham KL, Takada Y et al. Monkey rotavirus binding to alpha2beta1 integrin requires the alpha2 I domain and is facilitated by the homologous beta1 subunit. J Virol 2003; 77(17):9486-9501.
67. Graham KL, Halasz P, Tan Y et al. Integrin-using rotaviruses bind alpha2beta1 integrin alpha2 I domain via VP4 DGE sequence and recognize alphaXbeta2 and alphaVbeta3 by using VP7 during cell entry. J Virol 2003; 77(18):9969-9978.
68. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 1998; 282(5390):938-941.
69. Cormier EG, Tsamis F, Kajumo F et al. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 2004; 101(19):7270-7274.
70. Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: Potential receptors and their biological functions. J Gen Virol 2006; 87(Pt 5):1075-1084.
71. Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100(12):7271-7276.
72. Bartosch B, Vitelli A, Granier C et al. Cell entry of hepatitis C virus requires a set of coreceptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003; 278(43):41624-41630.
73. Reeves JD, Hibbitts S, Simmons G et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: Comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999; 73(9):7795-7804.
74. Kaleeba JA, Berger EA. Kaposi's sarcoma-associated herpesvirus fusion-entry receptor: Cystine transporter xCT. Science 2006; 311(5769):1921-1924.
75. Akula SM, Pramod NP, Wang FZ et al. Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 2002; 108(3):407-419.
76. Akula SM, Wang FZ, Vieira J et al. Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology 2001; 282(2):245-255.
77. Rappocciolo G, Jenkins FJ, Hensler HR et al. DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J Immunol 2006; 176(3):1741-1749.
78. Hong PW, Flummerfelt KB, de Parseval A et al. Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding. J Virol 2002; 76(24):12855-12865.
79. Su SV, Hong P, Baik S et al. DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. J Biol Chem 2004; 279(18):19122-19132.
80. Lee B, Leslie G, Soilleux E et al. cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol 2001; 75(24):12028-12038.
81. Nobile C, Petit C, Moris A et al. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J Virol 2005; 79(9):5386-5399.
82. Turville SG, Cameron PU, Handley A et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002; 3(10):975-983.
83. Snyder GA, Ford J, Torabi-Parizi P et al. Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigen-capturing rather than an adhesion receptor. J Virol 2005; 79(8):4589-4598.
84. Stahl-Hennig C, Steinman RM, Tenner-Racz K et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999; 285(5431):1261-1265.
85. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74(13):6087-6095.
86. Valladeau J, Ravel O, Dezutter-Dambuyant C et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000; 12(1):71-81.
87. Veazey RS, Shattock RJ, Pope M et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9(3):343-346.
88. Tassaneetrithep B, Burgess TH, Granelli-Piperno A et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197(7):823-829.
89. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 2003; 278(22):20358-20366.
90. Pohlmann S, Zhang J, Baribaud F et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003; 77(7):4070-4080.
91. Gardner JP, Durso RJ, Arrigale RR et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003; 100(8):4498-4503.
92. Halary F, Amara A, Lortat-Jacob H et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 2002; 17(5):653-664.
93. Alvarez CP, Lasala F, Carrillo J et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002; 76(13):6841-6844.
94. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100(5):587-597.
95. Nguyen DG, Hildreth JE. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol 2003; 33(2):483-493.
96. Reading PC, Miller JL, Anders EM. Involvement of the mannose receptor in infection of macrophages by influenza virus. J Virol 2000; 74(11):5190-5197.
97. Scarselli E, Ansuini H, Cerino R et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21(19):5017-5025.
98. Acton S, Rigotti A, Landschulz KT et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271(5248):518-520.
99. Landschulz KT, Pathak RK, Rigotti A et al. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996; 98(4):984-995.
100. Voisset C, Callens N, Blanchard E et al. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280(9):7793-7799.
101. Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981; 289(5796):366-373.
102. Weis W, Brown JH, Cusack S et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988; 333(6172):426-431.
103. Paulson JC, Sadler JE, Hill RL. Restoration of specific myxovirus receptors to asialoerythrocytes by incorporation of sialic acid with pure sialyltransferases. J Biol Chem 1979; 254(6):2120-2124.
104. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56:365-394.
105. Rogers GN, Paulson JC. Receptor determinants of human and animal influenza virus isolates: Differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 1983; 127(2):361-373.
106. Gambaryan AS, Robertson JS, Matrosovich MN. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 1999; 258(2):232-239.
107. Connor RJ, Kawaoka Y, Webster RG et al. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 1994; 205(1):17-23.
108. Daniels RS, Douglas AR, Skehel JJ et al. Antigenic analyses of influenza virus haemagglutinins with different receptor-binding specificities. Virology 1984; 138(1):174-177.
109. Superti F, Donelli G. Gangliosides as binding sites in SA-11 rotavirus infection of LLC-MK2 cells. J Gen Virol 1991; 72(Pt 10):2467-2474.
110. Fukudome K, Yoshie O, Konno T. Comparison of human, simian, and bovine rotaviruses for requirement of sialic acid in hemagglutination and cell adsorption. Virology 1989; 172(1):196-205.
111. Ciarlet M, Estes MK. Human and most animal rotavirus strains do not require the presence of sialic acid on the cell surface for efficient infectivity. J Gen Virol 1999; 80(Pt 4):943-948.
112. Guo CT, Nakagomi O, Mochizuki M et al. Ganglioside GM(1a) on the cell surface is involved in the infection by human rotavirus KUN and MO strains. J Biochem (Tokyo) 1999; 126(4):683-688.
113. Delorme C, Brussow H, Sidoti J et al. Glycosphingolipid binding specificities of rotavirus: Identification of a sialic acid-binding epitope. J Virol 2001; 75(5):2276-2287.
114. Willoughby RE. Rotaviruses preferentially bind O-linked sialylglycoconjugates and sialomucins. Glycobiology 1993; 3(5):437-445.
115. Kiefel MJ, Beisner B, Bennett S et al. Synthesis and biological evaluation of N-acetylneuraminic acid-based rotavirus inhibitors. J Med Chem 1996; 39(6):1314-1320.
116. Willoughby RE, Yolken RH. SA11 rotavirus is specifically inhibited by an acetylated sialic acid. J Infect Dis 1990; 161(1):116-119.
117. Fuentes-Panana EM, Lopez S, Gorziglia M et al. Mapping the hemagglutination domain of rotaviruses. J Virol 1995; 69(4):2629-2632.
118. Dormitzer PR, Sun ZY, Wagner G et al. The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site. EMBO J 2002; 21(5):885-897.
119. Fazli A, Bradley SJ, Kiefel MJ et al. Synthesis and biological evaluation of sialylmimetics as rotavirus inhibitors. J Med Chem 2001; 44(20):3292-3301.
120. Liakatos A, Kiefel MJ, Fleming F et al. The synthesis and biological evaluation of lactose-based sialylmimetics as inhibitors of rotaviral infection. Bioorg Med Chem 2006; 14(3):739-757.
121. Willoughby RE, Yolken RH, Schnaar RL. Rotaviruses specifically bind to the neutral glycosphingolipid asialo-GM1. J Virol 1990; 64(10):4830-4835.
122. Rolsma MD, Gelberg HB, Kuhlenschmidt MS. Assay for evaluation of rotavirus-cell interactions: Identification of an enterocyte ganglioside fraction that mediates group A porcine rotavirus recognition. J Virol 1994; 68(1):258-268.
123. Rolsma MD, Kuhlenschmidt TB, Gelberg HB et al. Structure and function of a ganglioside receptor for porcine rotavirus. J Virol 1998; 72(11):9079-9091.
124. Harouse JM, Collman RG, Gonzalez-Scarano F. Human immunodeficiency virus type 1 infection of SK-N-MC cells: Domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line. J Virol 1995; 69(12):7383-7390.
125. Yahi N, Baghdiguian S, Moreau H et al. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J Virol 1992; 66(8):4848-4854.
126. Bhat S, Spitalnik SL, Gonzalez-Scarano F et al. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci USA 1991; 88(16):7131-7134.
127. Bhat S, Mettus RV, Reddy EP et al. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. AIDS Res Hum Retroviruses 1993; 9(2):175-181.
128. Arnberg N, Edlund K, Kidd AH et al. Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol 2000; 74(1):42-48.
129. Gavrilovskaya IN, Shepley M, Shaw R et al. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA 1998; 95(12):7074-7079.
130. Tamura M, Natori K, Kobayashi M et al. Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J Virol 2004; 78(8):3817-3826.
131. Misinzo G, Delputte PL, Meerts P et al. Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells. J Virol 2006; 80(7):3487-3494.
132. Chen Y, Maguire T, Hileman RE et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997; 3(8):866-871.
133. Neyts J, Snoeck R, Schols D et al. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology 1992; 189(1):48-58.
134. Black JB, Pellett PE. Human herpesvirus 7. Rev Med Virol 1999; 9(4):245-262.
135. Krusat T, Streckert HJ. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 1997; 142(6):1247-1254.
136. Holmgren J, Svennerholm L, Elwing H et al. Sendai virus receptor: Proposed recognition structure based on binding to plastic-adsorbed gangliosides. Proc Natl Acad Sci USA 1980; 77(4):1947-1950.
137. Markwell MA, Svennerholm L, Paulson JC. Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci USA 1981; 78(9):5406-5410.
138. Roivainen M, Piirainen L, Hovi T et al. Entry of coxsackievirus A9 into host cells: Specific interactions with alpha v beta 3 integrin, the vitronectin receptor. Virology 1994; 203(2):357-365.
139. Uncapher CR, DeWitt CM, Colonno RJ. The major and minor group receptor families contain all but one human rhinovirus serotype. Virology 1991; 180(2):814-817.
140. Jackson T, Ellard FM, Ghazaleh RA et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 1996; 70(8):5282-5287.
141. Berinstein A, Roivainen M, Hovi T et al. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 1995; 69(4):2664-2666.
142. Nelsen-Salz B, Eggers HJ, Zimmermann H. Integrin alpha(v)beta3 (vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain Barty. J Gen Virol 1999; 80(Pt 9):2311-2313.
143. Chung CS, Hsiao JC, Chang YS et al. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998; 72(2):1577-1585.
144. Hsiao JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999; 73(10):8750-8761.
145. Maddon PJ, Dalgleish AG, McDougal JS et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47(3):333-348.
146. Ceccaldi PE, Delebecque F, Prevost MC et al. DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus Type 1-infected cells. J Virol 2006; 80(10):4771-4780.
147. Thoulouze MI, Lafage M, Schachner M et al. The neural cell adhesion molecule is a receptor for rabies virus. J Virol 1998; 72(9):7181-7190.
148. McGreal EP, Miller JL, Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol 2005; 17(1):18-24.
149. Lopez S, Arias CF. Multistep entry of rotavirus into cells: A Versaillesque dance. Trends Microbiol 2004; 12(6):271-278.